Koblenz, Germany — September 10, 2025 — Marking the 6th anniversary of its wholly-owned subsidiary Shanghai MicroPort CardioAdvent Co., Ltd., MicroPort CardioFlow Medtech Corporation (CardioFlow, 02160.HK) announced the successful completion of the first two clinical applications of its self-developed AnchorMan^® Left Atrial Appendage Closure (LAAC) System (AnchorMan^®) in Germany. The procedures were performed at Clinic of General Internal Medicine and Cardiology, Katholisches Klinikum Koblenz·Montabaur, a renowned hospital in Germany.

The hospital belongs to the largest church-affiliated healthcare group in Germany, with KKM being its main campus. The catheter procedures were led by Professor Jiangtao Yu, a renowned German-Chinese cardiovascular specialist, and his team. Both patients presented challenging cases with "reverse chicken-wing" morphology and shallow LAA anatomy. Despite these challenges, the AnchorMan^® devices were implanted stably, resulting in no peri-device leak and no clinical complications. The procedures were fully successful, and both patients were discharged smoothly the following day.

Case 1

The patient was an 84-year-old female with persistent atrial fibrillation (AF) who experienced intracranial hemorrhage after oral anticoagulation. Medical history included hypertension, hyperlipidemia, and status post dual-chamber pacemaker implantation. With a CHA₂DS₂-VASc score of 5 and a HAS-BLED score of 4, she was at high risk for both stroke and bleeding. Preoperative TEE confirmed the absence of thrombus in the left atrium and left atrial appendage.

LAA Measurement: The LAA had a reverse chicken-wing morphology. The ostium measured 20.82 mm, with a shallow depth of only 11.82 mm. A 23 mm AnchorMan^® device was selected for implantation.

Device Deployment: Utilizing the device's distal rounded design and high safety profile, the implanting team effectively utilized the available LAA depth by employing the unsheathing method for deployment. The 23 mm AnchorMan^® was successfully implanted in a single attempt, achieving complete closure.

Post-deployment, the device conformed well to the LAA anatomy. The tug test confirmed stable device position without displacement. The compression ratio was ideal, and the immediate sealing effect was excellent.

Final Release: The AnchorMan^® was successfully released. The device showed no shoulder protrusion and no residual shunt.

Procedure Outcome: Post-procedure, the AnchorMan^® was in an optimal position, stable on tug test, with a compression ratio of 10.4%, no residual shunt, and no complications.

Case 2

The patient was a 66-year-old male with persistent AF who experienced gastrointestinal bleeding after oral anticoagulation. Medical history included stroke, anemia, and chronic obstructive pulmonary disease (COPD). With a CHA₂DS₂-VASc score of 4 and a HAS-BLED score of 3, he was at high risk for both stroke and bleeding. Preoperative TEE confirmed the absence of thrombus in the left atrium and left atrial appendage.

LAA Measurement: The LAA ostium measured 18.27 mm with a depth of only 14.26 mm. A 23 mm AnchorMan^® device was selected for implantation.

Device Deployment and Release: The LAA was shallow, had a reverse chicken-wing morphology, was irregular, featured a longer orifice, and had poor coaxiality, posing significant challenges requiring advanced implant technique. Leveraging the operator's extensive experience and efficient team collaboration, the final release was successfully completed, resulting in no residual shunt.

Procedure Outcome: Post-procedure, the AnchorMan^® was in an optimal position, stable on tug test, with no residual shunt and no complications.

Expert Commentary

Professor Jiangtao Yu provided high praise for the product's clinical performance:

"The AnchorMan^® LAAC system features a short learning curve and is user-friendly. Both cases involved challenging anatomies with reverse chicken-wing morphology and shallow depth. AnchorMan^®, with its unique design featuring a 3D-folded, rounded distal end and strong radial force, reduces procedural uncertainty while enhancing safety and ease of use. The quality and performance of AnchorMan^® have reached internationally advanced levels. We look forward to its expanding impact, offering superior treatment options to more patients worldwide."

Summary

As the only semi-occlusive plug-type LAAC system approved in China, AnchorMan^® has now been used in nearly 1,000 clinical cases within the Chinese market. In February 2025, AnchorMan^® successfully obtained EU CE MDR certification, followed by the successful completion of its first overseas commercial implants in Poland, formally initiating its global journey. This successful entry into Germany, Europe's largest and the world's fourth-largest economy, signifies the growing recognition of its innovative technology and clinical value by the premium European market. Moving forward, the company will accelerate the global commercial rollout of AnchorMan^®, committed to providing AF patients worldwide with superior stroke prevention solutions.